Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Acute lymphoblastic leukemia (ALL) is diagnosed in 3000 to 4000 persons in the United
States each year; two thirds of them are children. 1, 2 The current rate of cure of nearly 80 …

Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a
member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In …

Abstract Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two
successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology …

Acute lymphoblastic leukemia and lymphoblastic lymphoma constitute a family of genetically
heterogeneous lymphoid neoplasms derived from B-and T-lymphoid progenitors. Diagnosis …

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly
heterogeneous disease comprising many entities for which distinct treatment strategies are …

Abstract Background Long non-coding RNAs (lncRNAs) play a variety of cellular roles,
including regulation of transcription and translation, leading to alterations in gene …

Treatment of acute lymphoblastic leukaemia (ALL) in adults presents a formidable
challenge. While overall results have improved over the past 3 decades, the long‐term …

Purpose The prognosis for older adolescents and young adults with acute lymphoblastic
leukemia (ALL) has been historically much worse than that for younger patients. We …

Childhood cancers are rare but an important cause of morbidity and mortality in children
younger than 15y of age. Common childhood malignancies include leukemias (commonest …